TY - JOUR
T1 - Correction to
T2 - Perinatal outcomes and long-term infectious morbidity of offspring born to mothers with familial Mediterranean fever (Archives of Gynecology and Obstetrics, (2023), 310, 3, (1417-1424), 10.1007/s00404-023-07317-w)
AU - Asher, Itay
AU - Sheiner, Eyal
AU - Willner, N. Tifferet
AU - Zeller, Lior
AU - Pariente, Gali
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.
PY - 2024/1/1
Y1 - 2024/1/1
N2 - This is a statement acknowledging that our article [1] includes text that first appeared in the UpToDate topic by Eldad Ben-Chetrit, “Gene test interpretation: MEFV (familial Mediterranean fever gene),” [2] and was reproduced without the permission of UpToDate, Inc. In this review, the author discusses (among others) the methods for diagnosis of FMF, the genetics of FMF, and their ramifications on offspring and at-risk relatives. The affected text in our article, which was reprinted from the above-mentioned UpToDate topic, can be found in the following sections and reads: 1. Study design: "The diagnosis of FMF was made on the basis of clinical symptoms and was supported by ethnic origin and family history. Genetic testing for FMF serves to support the diagnosis in patients who meet clinical criteria for FMF, to counsel at-risk relatives, and to guide the therapeutic approach. In individuals who met clinical criteria for FMF but in whom genetic testing was not diagnostic (only one or no pathogenic MEFV mutation), the diagnosis of FMF was supported by a 6-month trial of colchicine therapy that resulted in a relief of attacks and recurrence after cessation of treatment.” 2. Conclusion: “Children of an affected individual who has biallelic pathogenic variants in MEFV will be obligate carriers of one or the other variant. The children of such an individual could be affected with FMF if the other parent is also a carrier of a disease variant; as a result, such a child may inherit a pathogenic variant in MEFV from both parents. Nevertheless, some children may display FMF even with a single pathogenic variant they inherited from their parent who has biallelic variants [24]. Siblings of an individual with FMF whose parents are both unaffected carriers have a 25% chance of inheriting a pathogenic variant from both parents and being affected. They have a 50% chance of being heterozygous and unaffected and a 25% chance of not inheriting either of the pathogenic variants in MEFV [25]. Individuals who test positive for a pathogenic variant or likely pathogenic variant should inform their at-risk relatives about the importance of genetic counseling and possible testing if they have elevated acute phase reactants that are suggestive of subclinical inflammation". The appropriate clearances for reproducing the UpToDate content were not secured, nor was the content attributed in our article. We apologize for the oversight and extend our sincere apologies to the UpToDate author and to our readers. The original article has been corrected.
AB - This is a statement acknowledging that our article [1] includes text that first appeared in the UpToDate topic by Eldad Ben-Chetrit, “Gene test interpretation: MEFV (familial Mediterranean fever gene),” [2] and was reproduced without the permission of UpToDate, Inc. In this review, the author discusses (among others) the methods for diagnosis of FMF, the genetics of FMF, and their ramifications on offspring and at-risk relatives. The affected text in our article, which was reprinted from the above-mentioned UpToDate topic, can be found in the following sections and reads: 1. Study design: "The diagnosis of FMF was made on the basis of clinical symptoms and was supported by ethnic origin and family history. Genetic testing for FMF serves to support the diagnosis in patients who meet clinical criteria for FMF, to counsel at-risk relatives, and to guide the therapeutic approach. In individuals who met clinical criteria for FMF but in whom genetic testing was not diagnostic (only one or no pathogenic MEFV mutation), the diagnosis of FMF was supported by a 6-month trial of colchicine therapy that resulted in a relief of attacks and recurrence after cessation of treatment.” 2. Conclusion: “Children of an affected individual who has biallelic pathogenic variants in MEFV will be obligate carriers of one or the other variant. The children of such an individual could be affected with FMF if the other parent is also a carrier of a disease variant; as a result, such a child may inherit a pathogenic variant in MEFV from both parents. Nevertheless, some children may display FMF even with a single pathogenic variant they inherited from their parent who has biallelic variants [24]. Siblings of an individual with FMF whose parents are both unaffected carriers have a 25% chance of inheriting a pathogenic variant from both parents and being affected. They have a 50% chance of being heterozygous and unaffected and a 25% chance of not inheriting either of the pathogenic variants in MEFV [25]. Individuals who test positive for a pathogenic variant or likely pathogenic variant should inform their at-risk relatives about the importance of genetic counseling and possible testing if they have elevated acute phase reactants that are suggestive of subclinical inflammation". The appropriate clearances for reproducing the UpToDate content were not secured, nor was the content attributed in our article. We apologize for the oversight and extend our sincere apologies to the UpToDate author and to our readers. The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85211808507&partnerID=8YFLogxK
U2 - 10.1007/s00404-024-07853-z
DO - 10.1007/s00404-024-07853-z
M3 - Comment/debate
C2 - 39617852
AN - SCOPUS:85211808507
SN - 0932-0067
JO - Archives of Gynecology and Obstetrics
JF - Archives of Gynecology and Obstetrics
ER -